Today, the Supreme Court of India will decide on a matter that has a bearing on all current and future labouring mothers in India, a country that sees 26 million births each year. It will decide whether one southern Indian company should be given sole responsibility for manufacturing and supplying oxytocin for all of India’s women and animals.

Oxytocin is a critical part of the birthing process and is recommended as a first line drug to prevent and treat excess bleeding immediately after childbirth. With stakes this high, it’s little surprise that the oxytocin injection figures in the World Health Organisation’s Model List of Essential Medicines as well as India’s National List of Essential Medicines.

AUTHOR

Suraksha P

Suraksha writes on Healthcare and Pharma. She has been a journalist for five years, reporting for The New Indian Express in Bengaluru and Chennai, and The Times of India, Delhi. In her previous stints she has written on health, civic issues and education. She investigated cover up of corruption in the state health department’s think tank, narrated harrowing tales of women who underwent unwarranted hysterectomies, and wrote about how loss of biometrics came in the way of Leprosy patients getting an Aadhaar card and thereby pension. She can be reached at suraksha at the-ken dot com.

View Full Profile

Sign up to our India edition to read this story instantly

To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.

If you’ve already signed up, just enter your email below or login using Facebook or Google.